Beactica began IND-enabling studies for BEA-17, an oral degrader targeting LSD1 and CoREST being developed as a precision immunotherapy for glioblastoma. The company is working toward an EU clinical trial application or a U.S. IND next year, reflecting continued pharma interest in epigenetic degradation combined with immune-focused mechanisms.